362 related articles for article (PubMed ID: 28329731)
1. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
2. Peripheral Stem Cell Apheresis is Feasible Post
Kraal KCJM; Timmerman I; Kansen HM; van den Bos C; Zsiros J; van den Berg H; Somers S; Braakman E; Peek AML; van Noesel MM; van der Schoot CE; Fiocco M; Caron HN; Voermans C; Tytgat GAM
Clin Cancer Res; 2019 Feb; 25(3):1012-1021. PubMed ID: 30314967
[TBL] [Abstract][Full Text] [Related]
3. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Kraal KC; Tytgat GA; van Eck-Smit BL; Kam B; Caron HN; van Noesel M
Pediatr Blood Cancer; 2015 Nov; 62(11):1886-91. PubMed ID: 25981988
[TBL] [Abstract][Full Text] [Related]
4. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
de Kraker J; Hoefnagel KA; Verschuur AC; van Eck B; van Santen HM; Caron HN
Eur J Cancer; 2008 Mar; 44(4):551-6. PubMed ID: 18267358
[TBL] [Abstract][Full Text] [Related]
11. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
12. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
13. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
16. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial.
Klingebiel T; Berthold F; Treuner J; Schwabe D; Fischer M; Feine U; Maul FD; Waters W; Wehinger H; Niethammer D
Med Pediatr Oncol; 1991; 19(2):84-8. PubMed ID: 2011100
[TBL] [Abstract][Full Text] [Related]
17. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
18. The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.
Hamidieh AA; Beiki D; Paragomi P; Fallahi B; Behfar M; Fard-Esfahani A; Hosseini AS; Shamshiri A; Eftekhari M; Ghavamzadeh A
Pediatr Transplant; 2014 Aug; 18(5):510-7. PubMed ID: 24814429
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
[TBL] [Abstract][Full Text] [Related]
20. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
